Financing channel feed – Endpoints News

Financing channel feed

After decades in the big leagues, Martin Mackay is going small — and he's delighted

8 years ago

Protein degradation 2.0? Third Rock sinks $56M into Cedilla's unusual approach

8 years ago

Nextech leads a $56M round for the Revolution's move into the clinic

8 years ago

Hong Kong clears way for pre-revenue biotech IPOs, plans to accept listing applications by May

8 years ago

Biotech unicorn's 'brain' attracts a $115M mega-round as investors embrace AI upstart

8 years ago

In knockout IPO offerings, MorphoSys and Surface Oncology haul combined $316M in upsized deals

8 years ago

Kleiner Perkins’ Beth Seidenberg bumps Tmunity’s cell therapy round to a cool $135M

8 years ago

Flagship’s Evelo Biosciences pitches $100M IPO for a new platform of monoclonal microbials

8 years ago

Inventiva raises $44M as it preps for a PhIII NASH program, upcoming IIb readout

8 years ago

Former Novo chairman Göran Ando joins the board as Tessa bags $50M in additional funding

8 years ago

VC believers back a $41M game plan for Enterprise Therapeutics' new group of respiratory drugs

8 years ago

Tapping a biotech boom, China gene editing CRO Biocytogen bags $65M round for global expansion

8 years ago

Magenta bags $52M Series C for bone marrow transplant pipeline

8 years ago

Constellation joins the mega-round club with $100M raise and plans to pursue cancer studies

8 years ago

Leap of faith? Buzzy anti-aging biotech Unity pitches an $85M IPO based on mouse data

8 years ago

RA Capital jumps into the melee on TTR amyloidosis, backing a $91M development plan for a BridgeBio drug

8 years ago

On the heels of major Pfizer deal, Arvinas snags $55M Series C for protein degradation cancer programs

8 years ago

With $340M crossover fund, Sofinnova Partners pivots to late-stage biotech investments while maintaining European focus

8 years ago

Belldegrun teams with a group of top VC players to unveil a $295M biotech fund at Vida Ventures

8 years ago

Arie Belldegrun raises $300M, grabs Pfizer’s allogeneic CAR-T portfolio and launches a groundbreaking drive to commercialization

8 years ago

Backed by giants, antibiotics upstart Macrolide gets $20M and an ex-Novartis exec as CEO

8 years ago

Unum Therapeutics stumbles on its Nasdaq debut, raising $69M and some transparency issues

8 years ago

Versant-backed Tempest grabs a $70M round with plans to drive a slate of I/O drugs into the clinic

8 years ago

Works in mice? It’s a winner for Homology as IPO reaps $144M haul, with biotech on a roll

8 years ago

First page Previous page 129 130 131132133 134 135 Next page Last page